Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial
Thrombosis and Haemostasis, Volume 98, No. 2, Year 2007
Notification
URL copied to clipboard!
Description
A randomized double-blind clinical trial was performed to test the safety and efficacy of a low-molecular-weight heparin, tinzaparin (Innohep®), for the management of acute painful vasoocclusive crisis characteristic of sickle cell anemia (SCA). We studied 253 patients with acute painful crisis but with no other complications of SCA, randomized to treatment or control groups. In the treatment group, 127 patients received tinzaparin at 175 IU/kg, subcutaneous once daily, along with supportive care including morphine analgesia; in the control group, 126 patients received placebo and the same supportive care.The maximal experimental treatment period was seven days. Analysis revealed a statistically significant reduction in number of days with the severest pain score, overall duration of painful crisis, and duration of hospitalization (p <0.05 for each comparison of tinzaparin vs. placebo). The decline in pain intensity was sharper for tinzaparin-treated patients, and complications consisted of two minor bleeding events that were reported and treated by cessation of tinzaparin. This investigation demonstrated that tinzaparin, administered at its approved treatment regimen, reduced the severity and duration of acute crisis of SCA. © 2007 Schattauer GmbH, Stuttgart.
Authors & Co-Authors
Qari, Mohamad Hasan
Saudi Arabia, Jeddah
King Abdulaziz University
Aljaouni, Soad Khalil
Saudi Arabia, Jeddah
King Abdulaziz University
Alardawi, Mohamad Salleh
Saudi Arabia, Jeddah
King Abdulaziz University
Fatani, Huda
Saudi Arabia, Jeddah
King Abdulaziz University
Alsayes, Fatin Mohamad
Saudi Arabia, Jeddah
King Abdulaziz University
Zografos, Panagiotis
Greece, Athens
Leo Pharma Hellas
Alsaigh, Mohamad
Saudi Arabia, Jeddah
King Abdulaziz University
Alalfi, Adnan
Saudi Arabia, Jeddah
King Abdulaziz University
Alamin, Mohamad
Saudi Arabia, Jeddah
King Abdulaziz University
Gadi, Abdulilah
Saudi Arabia, Jeddah
King Abdulaziz University
Mousa, Shaker A.
United States, Albany
Albany College of Pharmacy and Health Sciences
Statistics
Citations: 122
Authors: 11
Affiliations: 3
Identifiers
Doi:
10.1160/TH06-12-0718
ISSN:
03406245
Research Areas
Disability
Study Design
Randomised Control Trial